Skip to main content
  1. 主页
  2. 产品
  3. 细胞分析
  4. 实时细胞分析

实时细胞分析

xCELLigence 实时细胞分析

Agilent xCELLigence 实时细胞分析 (RTCA) 技术为您带来了强大而简单的活细胞分析工具。通过无标记活细胞阻抗和成像技术持续监测细胞健康、行为和功能。

非侵入式生物传感器技术提供细胞数量、细胞形态、细胞-基底粘附强度和细胞屏障功能的定量读数结果。它可以实时监测各种生物过程，包括细胞粘附、细胞增殖以及药物、病毒和细胞介导的细胞毒性、干细胞分化、细胞屏障功能形成/破坏、GPCR 反应以及细胞侵袭和迁移，几乎不需要手动操作。

xCELLigence RTCA 系统提供了一种客观且高灵敏度的动力学分析方法，超越了传统的细胞形态分析，有助于更详细地了解细胞行为和功能。
学习工具
实时细胞分析 — 常见问题解答
细胞阻抗工作原理
细胞分析应用
细胞分析网络研讨会
xCELLigence 癌症免疫疗法手册
活细胞成像的研究进展

改进方法

产品

产品

|
|

按字母顺序排序

筛选
过滤器内容选择工具

需要帮助吗？使用选择工具找到产品。

精选资料

Assessing Water Cytotoxicity with an Impedance-Based, Real-Time, and Label-Free Cellular Assay

Noninvasive and continuous monitoring of the perturbation of cellular growth following exposure to the cumulative toxicants present in water samples.

  • 应用简报
  • 916.42 KB

Enhancing Immune Cell Cytotoxicity and Persistence Insights Using Real-Time Cell Analysis

This editorial will discuss the potency assays available for cellular immunotherapies, the regulatory criteria they must meet, and the challenges faced in measuring immune cell cytotoxicity.

  • 文献转载
  • 1.25 MB

Real-Time Antibody Internalization Assays with Agilent xCELLigence RTCA eSight

This application note demonstrates a robust method for performing real-time antibody internalization assays using the Agilent xCELLigence RTCA eSight combined with CypHer5E pH-sensitive dyes.

  • 应用简报
  • 4.38 MB
精选视频

xCELLigence RTCA eSight 实时活细胞分析产品视频

  • 00:05:08

xCELLigence RTCA DP 仪器 — 视频

  • 00:04:12

xCELLigence RTCA eSight 实时活细胞分析工作流程

  • 00:00:41

使用 xCELLigence RTCA eSight 对 3D 肿瘤细胞球体进行实时免疫细胞杀伤检测

  • 00:01:30
返回页首
精选新闻

Agilent xCELLigence RTCA 仪器助力 FDA 新批准疗法的效价测定程序开发

Agilent xCELLigence 实时细胞分析 (RTCA) 技术为 Autolus Therapeutics 公司最近获批的 CAR-T 疗法 AUCATZYL 提供了精准可靠的测试支持，有力推动了效价测定程序的开发与应用。安捷伦通过提供准确可靠的细胞分析技术，帮助 Autolus 建立了强大的分析方法。

  • 2025 年 7 月 15 日

Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products

The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 integrates the xCELLigence Real-Time Cell Analyzer (RTCA) HT instrument with the BioTek BioSpa 8 automated incubator to expand the screening throughput of your RTCA HT instrument to eight 384-well plates.

  • 2023 年 2 月 8 日
专题培训与活动

Advancing the Boundaries of Real-Time Live Cell Analysis

Watch our on-demand webinar to explore multiplexed real-time cellular analysis using Agilent xCELLigence RTCA technology.

网络研讨会/培训

In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme

Immuno-oncology research is changing the landscape of cancer treatment by harnessing the immune system to attack cancer cells. These immunotherapies utilize both the adaptive and innate arms of the immune system, playing a pivotal role in a host’s defense against tumors. Join the Agilent Immuno-Oncology webinar series and learn how experts in the field are making groundbreaking discoveries and taking steps towards a cancer-free world. Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion—complicating delivery and increasing costs—are major challenges in the field. Here we describe the development of in vivo DNA-launched BTEs (dBTEs) with highly focused targeting of interleukin-13 receptor a2 (IL-13Ra2), a glioblastoma cell-surface target. We developed 4 BTEs targeting 2 epitopes of IL-13Ra2 and studied how heavy-light chain orientation affects BTE function. The dBTEs induced T cell activation, cytokine production, and tumor cytolysis in the presence of IL-13Ra2+ tumor cells, but we observed unique patterns of immune activation. We found a strong correlation between granzyme B secretion and dBTE-induced cytolysis of specific and nonspecific tumors. We down-selected dBTE PB01-forward based on lower cytokine induction profile and highest activation specificity. In vivo, dBTE PB01-forward demonstrated an improved half-life versus intravenous recombinant BTE delivery. In an orthotopic glioblastoma model, dBTE PB01-forward controlled tumor growth, improving animal survival, supporting the hypothesis that the blood-brain barrier does not affect the function of systemically delivered dBTE. Further study of PB01-forward for targeting glioblastoma and other IL-13Ra2+ cancers is warranted.
网络研讨会/培训

Accelerating Antibody Therapeutics Development Webinar

Dr. Tsourkas describes how pAbBDs can accelerate the development of antibody-drug conjugates, allows for the exploration of new therapeutic paradigms.
网络研讨会/培训

Identifying Regulatory Mechanisms in Cancer Metastatic Processes with an Integrated Multi-omics Approach

Identifying Regulatory Mechanisms in Cancer Metastatic Processes with an Integrated Multi-omics Approach
网络研讨会/培训

0 选择的 COUNT_HERE 产品.

全部清除